Skip to main content

Table 5 Pain freedom at 0.5, 1, 1.5, and 2 h did not differ significantly between groups using and not using migraine preventive medications

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Hours after dosingLasmiditan dose (mg)Using preventivesNot using preventivesInteraction p-valueb
Pain freedom n/N (%)Odds ratioa (CI)Pain freedom n/N (%)Odds ratioa (CI)
0.5PBO2/196 (1.0) 13/867 (1.5)  
502/104 (1.9)1.9 (0.2, 20.9)9/452 (2.0)1.3 (0.5,3.4)0.714
1002/175 (1.1)1.2 (0.2, 8.2)14/860 (1.6)1.1 (0.5,2.3)0.904
2003/167 (1.8)1.8 (0.3, 10.7)22/879 (2.5)1.7 (0.8, 3.4)0.920
1.0PBO7/196 (3.6) 67/867 (7.7)  
507/104 (6.7)2.2 (0.6, 8.9)33/452 (7.3)0.9 (0.5, 1.5)0.316
10013/175 (7.4)2.2 (0.8, 5.6)91/860 (10.6)1.4 (1.0, 2.0)0.854
20018/167 (10.8)3.3 (1.3, 8.0)144/879 (16.4)2.3 (1.7, 3.2)0.889
1.5PBO13/196 (6.6) 114/867 (13.1)  
5017/104 (16.3)2.5 (1.0, 6.3)83/452 (18.4)1.3 (0.9, 1.8)0.196
10028/175 (16.0)2.7 (1.3, 5.3)188/860 (21.9)1.8 (1.4, 2.4)0.732
20031/167 (18.6)3.2 (1.6, 6.4)249/879 (28.3)2.6 (2.0, 3.3)0.656
2.0PBO23/196 (11.7) 172/867 (19.8)  
5025/104 (24.0)2.2 (1.0, 4.7)134/452 (29.6)1.4 (1.0, 1.9)0.715
10044/175 (25.1)2.5 (1.4, 4.4)265/860 (30.8)1.8 (1.4, 2.2)0.654
20051/167 (30.5)3.3 (1.9, 5.7)321/879 (36.5)2.3 (1.9, 2.9)0.550
  1. Abbreviations CI confidence interval, N number of patients in the subgroup of mITT population, n, number of patients achieving outcome, PBO placebo
  2. aOdds ratio compared to patients who received placebo in the same subgroup
  3. bComparing subgroups of patients who were using and not using migraine preventive medications for the stated time point and treatment group
\